Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lebrikizumab in pediatric moderate-to-severe atopic dermatitis (ADorable-2)
NCT05735483Phase 3Enrolling by invitation
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2023
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 3, double-blind trial of lebrikizumab in atopic dermatitis (AD) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Percentage of Participants Discontinued From Study Treatment due to Adverse Events at 52 weeks. Started Mar 2023; status: enrolling by invitation.
02
Drugs
lebrikizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05735483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05735483.